We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Pick Cactus (WHD) Stock Right Away
Read MoreHide Full Article
On Aug 21, Cactus, Inc. (WHD - Free Report) has been upgraded to a Zacks Rank #1 (Strong Buy), implying that the stock will significantly outperform the broader U.S. equity market over the next one to three months.
Why the Upgrade?
Over the past 30 days, the Zacks Consensus Estimate for 2018 earnings per share has been revised upward from $1.54 to $1.68. While the consensus estimate for 2019 bottom line has been moved north to $1.95 from $1.74. This adds to the company’s already impressive earnings profile. Cactus surpassed the Zacks Consensus Estimate in each of the prior three quarters.
Moreover, we expect the company to record revenue growth of 59.8% and 14.8% in 2018 and 2019, respectively.
As a leading manufacturer of advanced wellheads and pressure control equipment, the company’s business scenario seems favourable. The massive recovery of oil prices will likely convince oil and gas explorers to produce more of the commodities. This is expected to surge demand for Cactus’s highly-engineered equipment, which will be employed by explorers for drilling and completion of oil wells.
The company has already been gaining on higher revenues from heightened demand for its products. Through the first half of 2018, Cactus’ products line-up contributed to 52.1% of the company’s total revenues.
The company’s balance sheet has no outstanding debt. It’s cash balance stood at $28.4 million as of Jun 30, 2018. Moreover, under the revolving credit facility, the company has a capacity to borrow $50 million, reflecting the company’s financial strength.
The company’s pricing chart seems impressive. Over the past six months, the stock has surged 32.3%, outperforming the 20.1% collective gain of the stocks belonging to the industry.
McDermott’s earnings surpassed the Zacks Consensus Estimate in the last four quarters, the average positive surprise being 101.7%.
Petrobras’ bottom line beat the Zacks Consensus Estimate in three of the trailing four quarters, the average beat being 10.4%.
Helix Energy’s bottom line exceeded the consensus mark in three of the last four quarters, the average earnings surprise being 66.7%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Here's Why You Should Pick Cactus (WHD) Stock Right Away
On Aug 21, Cactus, Inc. (WHD - Free Report) has been upgraded to a Zacks Rank #1 (Strong Buy), implying that the stock will significantly outperform the broader U.S. equity market over the next one to three months.
Why the Upgrade?
Over the past 30 days, the Zacks Consensus Estimate for 2018 earnings per share has been revised upward from $1.54 to $1.68. While the consensus estimate for 2019 bottom line has been moved north to $1.95 from $1.74. This adds to the company’s already impressive earnings profile. Cactus surpassed the Zacks Consensus Estimate in each of the prior three quarters.
Moreover, we expect the company to record revenue growth of 59.8% and 14.8% in 2018 and 2019, respectively.
As a leading manufacturer of advanced wellheads and pressure control equipment, the company’s business scenario seems favourable. The massive recovery of oil prices will likely convince oil and gas explorers to produce more of the commodities. This is expected to surge demand for Cactus’s highly-engineered equipment, which will be employed by explorers for drilling and completion of oil wells.
The company has already been gaining on higher revenues from heightened demand for its products. Through the first half of 2018, Cactus’ products line-up contributed to 52.1% of the company’s total revenues.
The company’s balance sheet has no outstanding debt. It’s cash balance stood at $28.4 million as of Jun 30, 2018. Moreover, under the revolving credit facility, the company has a capacity to borrow $50 million, reflecting the company’s financial strength.
The company’s pricing chart seems impressive. Over the past six months, the stock has surged 32.3%, outperforming the 20.1% collective gain of the stocks belonging to the industry.
Other Stocks to Consider
Other top-ranked players in the energy space include McDermott International, Inc. , Petroleo Brasileiro S.A. or Petrobras (PBR - Free Report) and Helix Energy Solutions Group, Inc. (HLX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
McDermott’s earnings surpassed the Zacks Consensus Estimate in the last four quarters, the average positive surprise being 101.7%.
Petrobras’ bottom line beat the Zacks Consensus Estimate in three of the trailing four quarters, the average beat being 10.4%.
Helix Energy’s bottom line exceeded the consensus mark in three of the last four quarters, the average earnings surprise being 66.7%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>